Last reviewed · How we verify
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens is a Small molecule drug developed by University of Alabama at Birmingham. It is currently in Phase 1 development.
At a glance
| Generic name | NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens CI brief — competitive landscape report
- NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI
Frequently asked questions about NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
What is NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens?
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens is a Small molecule drug developed by University of Alabama at Birmingham.
Who makes NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens?
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens is developed by University of Alabama at Birmingham (see full University of Alabama at Birmingham pipeline at /company/university-of-alabama-at-birmingham).
What development phase is NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens in?
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens is in Phase 1.